Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14736880 | 1.00 | PIK3CD (0.71) | PIK3CDKCNH2 | |
| SCHEMBL14752199 | 1.00 | PIK3CD (0.71) | PIK3CDKCNH2 | |
| SCHEMBL29836161 | 1.00 | PIK3CD (0.71) | PIK3CDKCNH2 | |
| SCHEMBL30590310 | 1.00 | PIK3CD (0.71) | PIK3CDKCNH2 | |
| Trifluoroacetic Acid SCHEMBL23065009 | 0.95 | PIK3CD (0.65) | PIK3CDKCNH2 | |
| Trifluoroacetic Acid SCHEMBL14736642 | 0.95 | PIK3CD (0.65) | PIK3CDKCNH2 | |
| SCHEMBL21909924 | 0.93 | PIK3CD (0.78) | PIK3CD | |
| SCHEMBL14736080 | 0.93 | PIK3CD (0.78) | PIK3CD | |
| SCHEMBL14752107 | 0.93 | PIK3CD (0.78) | PIK3CD | |
| SCHEMBL30590287 | 0.93 | PIK3CD (0.78) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-10092570-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885KCNH2 3201/4885 |
| US-10092570-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885KCNH2 3201/4885 |
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885KCNH2 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.